Advertisement
Advertisement
U.S. Markets open in 6 hrs 13 mins
Advertisement
Advertisement
Advertisement
Advertisement

Xencor, Inc. (XNCR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
36.73+1.05 (+2.94%)
At close: 04:00PM EST
36.73 0.00 (0.00%)
After hours: 04:13PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close35.68
Open35.60
Bid0.00 x 800
Ask0.00 x 900
Day's Range34.84 - 37.05
52 Week Range30.12 - 58.35
Volume292,296
Avg. Volume207,331
Market Cap2.139B
Beta (5Y Monthly)0.71
PE Ratio (TTM)N/A
EPS (TTM)-1.11
Earnings DateFeb 21, 2022 - Feb 25, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est53.55
  • Benzinga

    Xencor Outlicenses Autoimmune Disease Candidate To Zenas BioPharma

    Zenas BioPharma has acquired from Xencor Inc (NASDAQ: XNCR) exclusive worldwide rights to develop, manufacture, and commercialize obexelimab. Obexelimab is a potential first-in-class bifunctional antibody that targets CD19 with its variable domain. It uses Xencor's XmAb Immune Inhibitor Fc Domain to target FcγRIIb, a receptor that inhibits the function of B-cells, which are essential components in the immune system. Under the terms of the new agreement, Zenas will issue a warrant giving Xencor t

  • Business Wire

    Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor

    MONROVIA, Calif., HONG KONG & BOSTON, November 21, 2021--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and Zenas BioPharma ("Zenas"), a global biopharmaceutical company based in the USA and China committed to the development and delivery of immune-based therapies, today announced that Zenas has acquired from Xencor exclusive worldwide rights to develop, manufac

  • Business Wire

    Xencor to Present at Upcoming Investor Conferences

    MONROVIA, Calif., November 19, 2021--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate at two upcoming investor conferences:

Advertisement
Advertisement